Drug Trial Radar · NCT04888715
To Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Sep 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jul 23, 2021
Primary completion
Aug 2, 2021
Study completion Aug 18, 2021
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- May 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An open label, 2-part, one-sequence, 3-period study to evaluate drug-drug interactions between DWN12088 and Pirfenidone or Nintedanib in healthy volunteers
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
DWN12088Drug
Prolyl-tRNA synthetase (PRS) inhibitor
PirfenidoneDrug
Pirfenidone
NintedanibDrug
Nintedanib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of Pirfenidone and DWN12088Time frame: 0hour (pre-dose), 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 10hour, 12hour
- AUC of Pirfenidone and DWN12088Time frame: 0hour (pre-dose), 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 10hour, 12hour
- Cmax of Nintedanib and DWN12088Time frame: 0hour (pre-dose), 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 10hour, 12hour
- AUC of Nintedanib and DWN12088Time frame: 0hour (pre-dose), 1hour, 2hour, 3hour, 4hour, 6hour, 8hour, 10hour, 12hour
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cha Unitersity Bundang Medical Center
Seongnam-si, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.